These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24399579)

  • 1. Quality of life of older patients undergoing renal transplantation: finding the right immunosuppressive treatment.
    Perlman RL; Rao PS
    Drugs Aging; 2014 Feb; 31(2):103-9. PubMed ID: 24399579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The first report from the patient outcomes registry for transplant effects on life (PORTEL): differences in side-effects and quality of life by organ type, time since transplant and immunosuppressive regimens.
    Hathaway D; Winsett R; Prendergast M; Subaiya I
    Clin Transplant; 2003 Jun; 17(3):183-94. PubMed ID: 12780666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients across Canada.
    Prasad GV; Nash MM; Keough-Ryan T; Shapiro RJ
    J Nephrol; 2010; 23(3):274-81. PubMed ID: 20383867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in kidney recipients: comparison of tacrolimus and cyclosporine-microemulsion.
    Reimer J; Franke GH; Philipp T; Heemann U
    Clin Transplant; 2002 Feb; 16(1):48-54. PubMed ID: 11982615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus and quality of life after kidney transplantation--a multicenter study.
    Bohlke M; Rocha M; Gomes RH; Marini SS; Terhorst L; Barcellos FC; Hallal PC; Casarini D; Irigoyen MC
    Clin Transplant; 2006; 20(4):504-8. PubMed ID: 16842529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.
    Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C
    Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up.
    Citterio F; Scatà MC; Romagnoli J; Pozzetto U; Nanni G; Castagneto M
    Transplant Proc; 2002 Aug; 34(5):1685-6. PubMed ID: 12176535
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
    Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
    Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus.
    Taylor DO; Barr ML; Radovancevic B; Renlund DG; Mentzer RM; Smart FW; Tolman DE; Frazier OH; Young JB; VanVeldhuisen P
    J Heart Lung Transplant; 1999 Apr; 18(4):336-45. PubMed ID: 10226898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
    Prasad GV; Nash MM; McFarlane PA; Zaltzman JS
    Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from cyclosporine to tacrolimus leads to improved disease-specific quality of life in patients after kidney transplantation.
    Franke GH; Trampenau C; Reimer J;
    Transplant Proc; 2006 Jun; 38(5):1293-4. PubMed ID: 16797285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.
    Webster A; Woodroffe RC; Taylor RS; Chapman JR; Craig JC
    Cochrane Database Syst Rev; 2005 Oct; (4):CD003961. PubMed ID: 16235347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60.
    Xenos EX; Ciancio G; Burke GW; Roth D; Miller J
    Clin Transplant; 1997 Oct; 11(5 Pt 2):497-9. PubMed ID: 9361949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppression, BK polyomavirus infections, and BK polyomavirus-specific T cells after pediatric kidney transplantation.
    Ahlenstiel-Grunow T; Pape L
    Pediatr Nephrol; 2020 Apr; 35(4):625-631. PubMed ID: 31858227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-center comparison between primary immunosuppression based on neoral cyclosporine and tacrolimus for renal transplantation.
    Pascual J; Marcén R; Burgos FJ; Tenorio MT; Merino JL; Arambarri M; Villafruela JJ; Liaño F; Mampaso F; Ortuño J
    Transplant Proc; 2002 Feb; 34(1):94-5. PubMed ID: 11959200
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
    Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
    Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression in older renal transplant patients.
    Morales JM; Campistol JM; Andrés A; Herrero JC
    Drugs Aging; 2000 Apr; 16(4):279-87. PubMed ID: 10874523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
    Ulsh PJ; Yang HC; Holman MJ; Ahsan N
    J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.